Latest Commercial Strategy News

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Galan Lithium has locked in a binding funding and offtake agreement with Authium Limited for its Hombre Muerto West project, significantly reducing capital and operating costs. The company raised approximately A$13 million via placement and plans further shareholder funding, aiming for lithium chloride production in H1 2026.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Lithium Universe Limited has signed a non-binding MOU with Lafarge Canada for exclusive supply of aluminosilicate from its Bécancour refinery, aiming to boost cement durability and sustainability in Canada’s growing market.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Canyon Resources announces Peter Secker as new CEO, signaling a strategic shift as the company advances its Minim Martap bauxite project toward production.

Green Technology Metals (GT1) is progressing its lithium conversion facility in Ontario, with pilot testing underway and a pre-feasibility study due in April 2025. The project aims to establish Ontario's first vertically integrated lithium concentrates and chemicals business, leveraging a strategic partnership with EcoPro.

Alpha HPA Limited has announced key leadership changes, appointing Rob Williamson as Managing Director to steer the company through its next growth phase, while Rimas Kairaitis shifts focus to commercial strategy. The retirement of long-serving director Peter Nightingale marks the end of an era.